SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. [electronic resource]
Producer: 20050818Description: 706-12 p. digitalISSN:- 0006-4971
- Antineoplastic Agents -- administration & dosage
- Apoptosis -- drug effects
- Bone Marrow Cells -- drug effects
- Caspases -- metabolism
- Cell Adhesion -- drug effects
- Cell Line, Tumor
- Cyclin D1 -- metabolism
- Dexamethasone -- administration & dosage
- Drug Resistance, Neoplasm
- Drug Synergism
- Etodolac -- administration & dosage
- Humans
- Insulin-Like Growth Factor I -- pharmacology
- Interleukin-6 -- pharmacology
- Multiple Myeloma -- drug therapy
- Myeloid Cell Leukemia Sequence 1 Protein
- Neoplasm Proteins -- metabolism
- Poly(ADP-ribose) Polymerases -- metabolism
- Proto-Oncogene Proteins c-bcl-2 -- metabolism
- Stereoisomerism
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.